| Mark David Menich, MD | |
|
3950 Broadway St, Boulder Valley Asthma And Allergy Clinics, Boulder, CO 80304-1104 | |
| (303) 444-5995 | |
| (303) 443-5030 |
| Full Name | Mark David Menich |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 37 Years |
| Location | 3950 Broadway St, Boulder, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417983438 | NPI | - | NPPES |
| 14209764 | Medicaid | CO |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boulder Valley Asthma And Allergy Clinics Pc | 4284659632 | 6 |
| Boulder Valley Asthma And Allergy Clinics Pc | 4284659632 | 6 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.
Scott Radloff, director of the Office of Population and Reproductive Health, writes about involving men in family planning on USAID's "Impact Blog."
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news conference on Monday at ENDO 2019, its annual meeting in New Orleans, La.
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.
"After years of individual cancer centers exploring ways to recruit more people from minority populations for cancer studies, $3.8 million in federal stimulus money has been awarded to five institutions — including M.D. Anderson (Cancer Center at the University of Texas) — to work on the issue together for the next two years. The National Center on Minority Health and Health Disparities, part of the National Institutes of Health, funded the project."
› Verified 9 days ago
| Entity Name | Boulder Valley Asthma & Allergy Clinics Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952522997 PECOS PAC ID: 4284659632 Enrollment ID: O20051013001064 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.
Scott Radloff, director of the Office of Population and Reproductive Health, writes about involving men in family planning on USAID's "Impact Blog."
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news conference on Monday at ENDO 2019, its annual meeting in New Orleans, La.
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.
"After years of individual cancer centers exploring ways to recruit more people from minority populations for cancer studies, $3.8 million in federal stimulus money has been awarded to five institutions — including M.D. Anderson (Cancer Center at the University of Texas) — to work on the issue together for the next two years. The National Center on Minority Health and Health Disparities, part of the National Institutes of Health, funded the project."
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark David Menich, MD 3950 Broadway St, Boulder Valley Asthma And Allergy Clinics, Boulder, CO 80304-1104 Ph: (303) 444-5995 | Mark David Menich, MD 3950 Broadway St, Boulder Valley Asthma And Allergy Clinics, Boulder, CO 80304-1104 Ph: (303) 444-5995 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.
Scott Radloff, director of the Office of Population and Reproductive Health, writes about involving men in family planning on USAID's "Impact Blog."
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news conference on Monday at ENDO 2019, its annual meeting in New Orleans, La.
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.
"After years of individual cancer centers exploring ways to recruit more people from minority populations for cancer studies, $3.8 million in federal stimulus money has been awarded to five institutions — including M.D. Anderson (Cancer Center at the University of Texas) — to work on the issue together for the next two years. The National Center on Minority Health and Health Disparities, part of the National Institutes of Health, funded the project."
› Verified 9 days ago
Dr. Marshelle Smith Warren, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 1460 Ithaca Dr, Boulder, CO 80305 Phone: 303-589-1304 | |
Karen M Andrews, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2750 Broadway St, Boulder, CO 80304 Phone: 303-440-3000 |